scholarly journals Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

2011 ◽  
Vol 52 (4) ◽  
pp. e56-e93 ◽  
Author(s):  
Alison G. Freifeld ◽  
Eric J. Bow ◽  
Kent A. Sepkowitz ◽  
Michael J. Boeckh ◽  
James I. Ito ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Infectious Diseases ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Antimicrobial Agents ◽  
Patients With Cancer ◽  
Neutropenic Patients

2018 Infectious Diseases Society of America Clinical Practice Guideline for the Management of Outpatient Parenteral Antimicrobial Therapya

2018 ◽  
Vol 68 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Anne H Norris ◽  
Nabin K Shrestha ◽  
Genève M Allison ◽  
Sara C Keller ◽  
Kavita P Bhavan ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Infectious Diseases ◽  
Antimicrobial Stewardship ◽  
Antimicrobial Therapy ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Healthcare Professionals ◽  
Outpatient Parenteral Antimicrobial Therapy ◽  
Infusion Catheter

Abstract A panel of experts was convened by the Infectious Diseases Society of America to update the 2004 clinical practice guideline on outpatient parenteral antimicrobial therapy (OPAT) [1]. This guideline is intended to provide insight for healthcare professionals who prescribe and oversee the provision of OPAT. It considers various patient features, infusion catheter issues, monitoring questions, and antimicrobial stewardship concerns. It does not offer recommendations on the treatment of specific infections. The reader is referred to disease- or organism-specific guidelines for such support.

scholarly journals Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients

2020 ◽  
Vol 38 (27) ◽  
pp. 3205-3216
Author(s):  
Thomas Lehrnbecher ◽  
Brian T. Fisher ◽  
Bob Phillips ◽  
Melissa Beauchemin ◽  
Fabianne Carlesse ◽  
...  
Keyword(s):  
Systematic Review ◽  
Stem Cell ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Pediatric Patients ◽  
Antifungal Prophylaxis ◽  
Hematopoietic Stem ◽  
Strong Recommendation ◽  
Patients With Cancer

PURPOSE To develop a clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation (HSCT) recipients. METHODS Recommendations were developed by an international multidisciplinary panel that included a patient advocate. We conducted a systematic review of systemic antifungal prophylaxis in children and adults with cancer and HSCT recipients. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to make strong or weak recommendations and to classify level of evidence as high, moderate, low, or very low. The panel considered directness of the data to pediatric patients. RESULTS There were 68 randomized trials included in the systematic review, of which 6 (9%) were conducted in a solely pediatric population. Strong recommendations were made to administer systemic antifungal prophylaxis to children and adolescents receiving treatment of acute myeloid leukemia, to those undergoing allogeneic HSCT pre-engraftment, and to those receiving systemic immunosuppression for graft-versus-host disease treatment. A strong recommendation was made to administer a mold-active agent with an echinocandin or a mold-active azole when systemic antifungal prophylaxis is warranted. For children younger than 13 years of age, an echinocandin, voriconazole, or itraconazole is suggested. Posaconazole may also be used in those age 13 years or older. A strong recommendation against routine administration of amphotericin as systemic antifungal prophylaxis was made. CONCLUSION We developed a clinical practice guideline for systemic antifungal prophylaxis administration in pediatric patients with cancer and HSCT recipients. Implementation and assessment of guideline-concordant rates and impacts are important future steps.

scholarly journals American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer

2010 ◽  
Vol 6 (6) ◽  
pp. 317-320 ◽  
Author(s):  
J. Douglas Rizzo ◽  
Melissa Brouwers ◽  
Patricia Hurley ◽  
Jerome Seidenfeld ◽  
Mark R. Somerfield ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Oncology ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Adult Patients ◽  
Patients With Cancer ◽  
Clinical Questions ◽  
American Society ◽  
Esa Therapy

This guideline update addresses two clinical questions: (1) What are the defining features of patients with a malignancy who are appropriate candidates for ESA treatment? (2) For patients who are appropriate candidates for treatment with ESAs, what are the optimal approaches to ESA therapy?

scholarly journals Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline

2015 ◽  
Vol 35 (2) ◽  
pp. 95-106 ◽  
Author(s):  
Fahad Al-Hameed ◽  
Hasan M Al-Dorzi ◽  
Abdulkarim Al Momen ◽  
Farjah Algahtani ◽  
Hazzaa Al Zahrani ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Venous Thromboembolism ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Patients With Cancer
Sign in / Sign up

Export Citation Format

Share Document